N/A N=120 A Prospective Trial of a Bio-absorbable Mesh in Challenging Laparoscopic Ventral or Incisional Hernia Repair
Hernia, Ventral · Incisional Hernia
Primary: Surgical Site Occurrence Rate — 1 subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=25 Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Polycystic Ovary Syndrome · Hyperandrogenism
Primary: Change in Progesterone Sensitivity Index Before and After Metformin Treatment. — -4.12; -4.29 % change in LH pulses/day 7 P4 level
Phase 2 N=154 A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
Diabetes Mellitus, Type 2
Primary: Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 Milligrams Per Deciliter (mg/dL)) Measured Using CGM (Continuous Glucose Monitoring) — 65.99; 72.86; 64.98…
Phase 3 N=36 Histrelin Subcutaneous Implant in Children With Central Precocious Puberty
Central Precocious Puberty
Primary: Luteinizing Hormone (LH) — 0.88; 0.53; 0.07; 0.50 MIU/ML
Phase 2 N=50 Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
Colorectal Carcinoma · CRC
Primary: Determine Radiographic Response Rate of Patients Enrolled in the Phase 2a Portion of the Study — 0; 0; 0; 1 Participants
N/A N=25,871 Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain
Autoimmune Diseases · Systemic Inflammatory Process · Knee Pain Chronic
Primary: Serum Levels of Biomarkers of Systemic Inflammation: Interleukin-6 (IL-6) — 1.71; 1.68; 1.69; 1.70 pg/ml — p=0.02
N/A N=48 InterStim® Amplitude Study
Urinary Urge Incontinence
Primary: Change in Urinary Urge Incontinence (UUI) Episodes Per Day From Baseline to 12 Weeks. — 4.4; 5.3; 5.1; 1.4 UUI episodes/day
Phase 1 N=65 Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 21; 22; 11; 1 Participants
N/A N=56 Gait Modifications and Cutaneous Stimulation
Osteoarthritis, Knee
Primary: Change in Peak Knee Flexion Moment (%Bw*Ht) — 2.72 %Bw*Ht — p=0.44
Phase 1 N=80 Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms — 19; 18; 7; 15 Participants
N/A N=85 ReFlow Medical Wingman Catheter Wing-IT Clinical Trial
Chronic Total Occlusion of Artery of the Extremities
Primary: Number of Lesions With Successful CTO Crossing Assessed by Angiography — 77 lesions
Phase 2 N=25 A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Primary: Overall Response Rate — 12 Participants — p=0.044
N/A N=824 Assessing the Impact of myHealth Rewards New Hire Enrollment Emails
Health Promotion · Wellness Programs
Primary: Number of People Enrolled Within 7 Days — 131; 130 Participants — p=.828
N/A N=6,915 Trends in Modern Phase 1 Oncology Trials
Cancer
Primary: Response Rate — 1371 Participants
Phase 3 N=292 Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
Fungal Infection · Hematopoietic and Lymphoid Cell Neoplasm
Primary: 42-day-cumulative Incidence of Proven or Probable Invasive Fungal Infections (IFI) — 1.4; 1.4 percentage of patients